产品说明书

Avanafil

Print
Chemical Structure| 330784-47-9 同义名 : TA1790
CAS号 : 330784-47-9
货号 : A803364
分子式 : C23H26ClN7O3
纯度 : 98%
分子量 : 483.951
MDL号 : MFCD11977961
存储条件：

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 15 mg/mL(30.99 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • PDE5

    PDE5, IC50:1 nM
描述 Avanafil (TA-1790) exhibits strong and specific inhibitory effects on phosphodiesterase-5 (PDE-5), with IC50 values being 5.2 nM for PDE-5 and progressively higher for PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2, and PDE-1. It enhances the NO/cGMP/PKG signaling pathway, leading to a reduction in bone mineral density (BMD) loss, bone weakening, and oxidative stress. By preventing the breakdown of cyclic guanosine monophosphate (cGMP), Avanafil elevates cGMP levels, making it a candidate for studies on erectile dysfunction and osteoporosis[1][2][3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.33mL

2.07mL

1.03mL

20.66mL

4.13mL

2.07mL
参考文献

[1]Huyut Z, et, al. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. Med Sci Monit Basic Res. 2018 Mar 13;24:47-58.

[2]Yilmaz D, et, al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014 Feb;83(2):508.e7-12.

[3]Kotera J, et, al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.